Giuseppe Biondi-Zoccai

@gbiondizoccai@mastodon.world
19 Followers
33 Following
366 Posts
Academic cardiologist, statistician/data scientist, medical writer/reviewer/editor.
Opinions own, (re)toots/likes ≠ endorsement/medical advice.
Polypills and cardiovascular prevention: dream wedding or ménage à trois (or quatre, cinq, six…)?
https://www.escardio.org/Sub-specialty-communities/European-Association-of-Preventive-Cardiology-(EAPC)/News/polypills-and-cardiovascular-prevention
Polypills and cardiovascular prevention: dream wedding or ménage à trois (or quatre, cinq, six…)?

Your access to the latest cardiovascular news, science, tools and resources.

Attendiamo la tua opinione sulla vaccinazione anti-influenzale nei pazienti adulti, con particolare attenzione a chi soffre di malattie cardiovascolari, completando questo sondaggio, parte del FLUence Project della World Heart Federation: https://es.surveymonkey.com/r/N2PHB9M
Sondaggio della Federazione Mondiale del Cuore

Take this survey powered by surveymonkey.com. Create your own surveys for free.

Please provide your opinion on influenza vaccination in adult patients, with a focus on people living with cardiovascular diseases, by completing this survey, part of the FLUence Project of the World Heart Federation: https://es.surveymonkey.com/r/K3TCPMT
World Heart Federation Global Survey

Take this survey powered by surveymonkey.com. Create your own surveys for free.

Role of Cardiovascular Imaging in Risk Assessment: Recent Advances, Gaps in Evidence, and Future Directions, by Perone et al
https://www.mdpi.com/2077-0383/12/17/5563
Role of Cardiovascular Imaging in Risk Assessment: Recent Advances, Gaps in Evidence, and Future Directions

Optimal risk assessment for primary prevention remains highly challenging. Recent registries have highlighted major discrepancies between guidelines and daily practice. Although guidelines have improved over time and provide updated risk scores, they still fail to identify a significant proportion of at-risk individuals, who then miss out on effective prevention measures until their initial ischemic events. Cardiovascular imaging is progressively assuming an increasingly pivotal role, playing a crucial part in enhancing the meticulous categorization of individuals according to their risk profiles, thus enabling the customization of precise therapeutic strategies for patients with increased cardiovascular risks. For the most part, the current approach to patients with atherosclerotic cardiovascular disease (ASCVD) is homogeneous. However, data from registries (e.g., REACH, CORONOR) and randomized clinical trials (e.g., COMPASS, FOURIER, and ODYSSEY outcomes) highlight heterogeneity in the risks of recurrent ischemic events, which are especially higher in patients with poly-vascular disease and/or multivessel coronary disease. This indicates the need for a more individualized strategy and further research to improve definitions of individual residual risk, with a view of intensifying treatments in the subgroups with very high residual risk. In this narrative review, we discuss advances in cardiovascular imaging, its current place in the guidelines, the gaps in evidence, and perspectives for primary and secondary prevention to improve risk assessment and therapeutic strategies using cardiovascular imaging.

MDPI
Role of Cardiovascular Imaging in Risk Assessment: Recent Advances, Gaps in Evidence, and Future Directions, by Perone et al
https://www.mdpi.com/2077-0383/12/17/5563
Role of Cardiovascular Imaging in Risk Assessment: Recent Advances, Gaps in Evidence, and Future Directions

Optimal risk assessment for primary prevention remains highly challenging. Recent registries have highlighted major discrepancies between guidelines and daily practice. Although guidelines have improved over time and provide updated risk scores, they still fail to identify a significant proportion of at-risk individuals, who then miss out on effective prevention measures until their initial ischemic events. Cardiovascular imaging is progressively assuming an increasingly pivotal role, playing a crucial part in enhancing the meticulous categorization of individuals according to their risk profiles, thus enabling the customization of precise therapeutic strategies for patients with increased cardiovascular risks. For the most part, the current approach to patients with atherosclerotic cardiovascular disease (ASCVD) is homogeneous. However, data from registries (e.g., REACH, CORONOR) and randomized clinical trials (e.g., COMPASS, FOURIER, and ODYSSEY outcomes) highlight heterogeneity in the risks of recurrent ischemic events, which are especially higher in patients with poly-vascular disease and/or multivessel coronary disease. This indicates the need for a more individualized strategy and further research to improve definitions of individual residual risk, with a view of intensifying treatments in the subgroups with very high residual risk. In this narrative review, we discuss advances in cardiovascular imaging, its current place in the guidelines, the gaps in evidence, and perspectives for primary and secondary prevention to improve risk assessment and therapeutic strategies using cardiovascular imaging.

MDPI
Del Nido cardioplegia for cardiac surgery requiring cardiopulmonary bypass: is the best yet to come? by Saade, Frati, Gaudio, et al
https://journals.lww.com/jcardiovascularmedicine/citation/2023/10000/del_nido_cardioplegia_for_cardiac_surgery.3.aspx
Del Nido cardioplegia for cardiac surgery requiring... : Journal of Cardiovascular Medicine

An abstract is unavailable.

LWW
Prognostic Impact of Mitral Regurgitation Before and After Transcatheter Aortic Valve Replacement in Patients With Severe Low‐Flow, Low‐Gradient Aortic Stenosis, by Ferruzzi et al
https://www.ahajournals.org/doi/10.1161/JAHA.123.029553
A hidden gem from our past as medical students: a letter of comment in The Lancet authored by Pierfrancesco Agostoni and myself when we were, respectively, 24 and 25 years old! https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(05)74135-0/fulltext
High dose esomeprazole as an anti-inflammatory agent in sepsis: Protocol for a randomized controlled trial, by Monti et al
https://www.sciencedirect.com/science/article/pii/S1551714423002422
Management of Coronary Artery Disease in Older Adults: Recent Advances and Gaps in Evidence, by Cacciatore et al https://www.mdpi.com/2077-0383/12/16/5233
Management of Coronary Artery Disease in Older Adults: Recent Advances and Gaps in Evidence

Coronary artery disease (CAD) is highly prevalent in older adults, yet its management remains challenging. Treatment choices are made complex by the frailty burden of older patients, a high prevalence of comorbidities and body composition abnormalities (e.g., sarcopenia), the complexity of coronary anatomy, and the frequent presence of multivessel disease, as well as the coexistence of major ischemic and bleeding risk factors. Recent randomized clinical trials and epidemiological studies have provided new data on optimal management of complex patients with CAD. However, frail older adults are still underrepresented in the literature. This narrative review aims to highlight the importance of assessing frailty as an aid to guide therapeutic decision-making and tailor CAD management to the specific needs of older adults, taking into account age-related pharmacokinetic and pharmacodynamic changes, polypharmacy, and potential drug interactions. We also discuss gaps in the evidence and offer perspectives on how best in the future to optimize the global strategy of CAD management in older adults.

MDPI